The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists

Dara L. Eckerle Mize; Marzieh Salehi

doi:10.1007/s11892-013-0377-9

The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists

Dara L. Eckerle Mize, Marzieh Salehi

Research output: Contribution to journal › Article

18 Scopus citations

Abstract

Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.

Original language	English (US)
Pages (from-to)	307-318
Number of pages	12
Journal	Current Diabetes Reports
Volume	13
Issue number	3
DOIs	https://doi.org/10.1007/s11892-013-0377-9
State	Published - Jun 1 2013
Externally published	Yes

Keywords

Cardiovascular risk factors
DPP-4
DPP-4 inhibitors
GLP-1
GLP-1 receptor agonists
Hypoglycemia
Incretin
Type 2 diabetes
Weight loss

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s11892-013-0377-9

Fingerprint Dive into the research topics of 'The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists'. Together they form a unique fingerprint.

Cite this

Eckerle Mize, D. L., & Salehi, M. (2013). The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists. Current Diabetes Reports, 13(3), 307-318. https://doi.org/10.1007/s11892-013-0377-9

@article{3fe6d5cd634146bfb20ebef99ba7f2d9,

title = "The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists",

abstract = "Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.",

keywords = "Cardiovascular risk factors, DPP-4, DPP-4 inhibitors, GLP-1, GLP-1 receptor agonists, Hypoglycemia, Incretin, Type 2 diabetes, Weight loss",

author = "{Eckerle Mize}, {Dara L.} and Marzieh Salehi",

year = "2013",

month = jun,

day = "1",

doi = "10.1007/s11892-013-0377-9",

language = "English (US)",

volume = "13",

pages = "307--318",

journal = "Current Diabetes Reports",

issn = "1534-4827",

publisher = "Current Medicine Group",

number = "3",

}

TY - JOUR

T1 - The place of GLP-1-based therapy in diabetes management

T2 - Differences between DPP-4 inhibitors and GLP-1 receptor agonists

AU - Eckerle Mize, Dara L.

AU - Salehi, Marzieh

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.

AB - Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.

KW - Cardiovascular risk factors

KW - DPP-4

KW - DPP-4 inhibitors

KW - GLP-1

KW - GLP-1 receptor agonists

KW - Hypoglycemia

KW - Incretin

KW - Type 2 diabetes

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=84877757399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877757399&partnerID=8YFLogxK

U2 - 10.1007/s11892-013-0377-9

DO - 10.1007/s11892-013-0377-9

M3 - Article

C2 - 23479200

AN - SCOPUS:84877757399

VL - 13

SP - 307

EP - 318

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 3

ER -